Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size .37; P=0.025), using prespecified analytic methodology memorialized in FDA Special Protocol Agreement. Levels of akathisia with NRX-101 were essentially zero at day 42 This safety advantage was previously reported in the Company's published STABIL-B trial Akathisia is identified as a life-threatening side effec ...

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to lurasidone - never previously shown with an oral antidepressant. Suicidality signal met the study's promising zone criteria and the akathisia signal approached statistical significance (P=0.076)  Both NRX-101 and lurasidone, an accepted standard of care in Bipolar Depression, demonstrated approximately 50% ...

The most recent trading session ended with NRx Pharmaceuticals, Inc. (NRXP) standing at $3.14, reflecting a +0.64% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.46%. On the other hand, the Dow registered a loss of 0.98%, and the technology-centric Nasdaq decreased by 0.64%.Shares of the company have depreciated by 41.13% over the course of the past month, underperforming the Medical sector's loss of 4.9% and the S&P 500's loss of 3.04%.Investors will be eag ...

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2023 Earnings Conference Call April 1, 2024 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder & Chief Scientist Stephen Willard - Chief Executive Officer Richard Narido - Chief Financial Officer & Treasurer Conference Call Participants Tim Moore - EF Hutton Ed Woo - Ascendiant Capital Operator Good morning everyone and welcome to the NRx Pharmaceuticals, Inc. Fourth Quarter and Full Year 2023 Results Conference Call. [ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-2844431 (State or ...

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Stephen Willard - Chief Executive Officer Jonathan Javitt - Founder & Chief Scientist Richard Narido - Chief Financial Officer & Treasurer Conference Call Participants Ed Woo - Ascendiant Capital Operator Thank you for standing by. This is the conference operator. Welcome to NRX Pharmaceuticals' Third Quarter 2023 Earnings Conference Call. As a rem ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-2844431 ...

NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Steve Willard - CEO & Director Jonathan Javitt - Chief Scientist & Director Seth Voorhees - CFO Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Good day and welcome to the NRX Pharmaceuticals Incorporated Second Quarter 2023 Earnings Conference Call. [Operator Instructions]. I would now like to turn the conference over to Mr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-2844431 (Stat ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2023 Earnings Call May 16, 2023 8:30 AM ET Company Participants Suzanne Messere - Investor Relations, Stern Stephen Willard - Chief Executive Officer and Director Seth Van Voorhees - Chief Financial Officer Jonathan C. Javitt - Chief Scientist and Director Conference Call Participants Edward Woo - Ascendiant Capital Markets LLC Jason Kolbert - Dawson James Securities Operator Good day, everyone, and welcome to NRx Pharmaceuticals’ First Quarter 2023 Earnings Confer ...